ATRi are candidates to selectively increase the effectiveness of radiation chemotherapy in ARID1A deficient rectal carcinoma cells in the clinic, as small to moderate increase in cell death after conventional radiation dose fraction of 1.8 Gy can be potentiated during the fractionated application of IR. The gene discussed is ARID1A; the disease is rectal carcinoma.